| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
- Buserelin
-
-
2026-08-25
- CAS:57982-77-1
- Min. Order: 1g
- Purity: 0.99
- Supply Ability: 1000kg
- BUSERELIN
-
-
2025-08-20
- CAS:57982-77-1
- Min. Order: 1Box
- Purity: 99.99%
- Supply Ability: 10 Boxes
- BUSERELIN
-
- $40.00
-
2025-06-20
- CAS:57982-77-1
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 10 tons
|
| Product Name: | BUSERELIN | | Synonyms: | (d-ser(bu(supt)(sup6)))-lh-rh(1-9)nonapeptide-ethylamide;(d-ser(tbu)(sup6)-ea(sup10))-lhrh;(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormon;(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormone;BUSERELIN;1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-;Buserilin;BUSERELIN PH. EUR. | | CAS: | 57982-77-1 | | MF: | C60H86N16O13 | | MW: | 1239.43 | | EINECS: | 261-061-9 | | Product Categories: | hormones;57982-77-1 | | Mol File: | 57982-77-1.mol |  |
| | BUSERELIN Chemical Properties |
| alpha | D20 -40.4° (c = 1 in dimethylacetamide) | | Boiling point | 845.19°C (rough estimate) | | density | 1.0711 (rough estimate) | | refractive index | 1.6200 (estimate) | | solubility | Sparingly soluble in water and in dilute acids. | | pka | 9.82±0.15(Predicted) | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic | | Major Application | pharmaceutical (small molecule) | | InChIKey | CUWODFFVMXJOKD-UHFFFAOYSA-N |
| WGK Germany | WGK 3 | | HS Code | 2937190000 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 4 Oral
Repr. 1B |
| | BUSERELIN Usage And Synthesis |
| Preparation | combined solid-phase and liquid-phase peptide synthesis method was employed. Using acid-labile 2-chlorotriphenylchloro resin (2-CTC resin), N,N-diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBT) were used as condensing agents to gradually condense and obtain the busereline intermediate peptide resin. The intermediate was then cleaved with a low-concentration acid to obtain a fully protected busereline intermediate. In the liquid phase, ethylamine was added to achieve N-terminal modification. Catalytic hydrogenation was then used to remove the nitro group from the arginine side chain and the benzyl group from the tyrosine side chain. A suitable acid concentration was selected to remove the triphenylmethyl protecting group while retaining the tert-butyl group of D-serine to obtain the crude peptide. Finally, semi-preparative purification and lyophilization yielded high-purity busereline. | | Description | Buserelin (Suprefact) is a hormonal therapy drug used to treat advanced prostate cancer. It is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat. | | Chemical Properties | White or slightly yellowish powder, hygroscopic. | | Uses | Gonad-stimulating principle. | | Definition | ChEBI: Buserelin is an oligopeptide. | | Brand name | Suprefact
(Hoechst-Roussel). | | Clinical Use |
Treatment of advanced prostate cancer and
endometriosis
Pituitary desensitisation in preparation for ovulation
induction regimens using gonadotrophins | | Side effects | Using too much Buserelin Injection may make you feel weak, nervous, dizzy and sick. You may also have a headache, hot flushes, stomach pain, swelling of the legs and breast pain. You may also have pain, bleeding or hardening of the skin at the site of injection | | Metabolism | Metabolic inactivation by peptides occurs in the liver
and kidney. The drug is also inactivated by pituitary
membrane enzymes.
Excreted in the urine and bile as unchanged drug and
metabolites. | | Description | Buserelin contains 9 amino acids Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt and having a molecular weight of 1239.44 Dalton. | | Background | Buserelin belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). It acts on the pituitary gland which controls the amount of many different types of hormones (chemical messengers). It alters the amount of hormones, particularly the oestrogens androgens. This alteration of hormone levels can be exploited to treat cancers of the prostate gland, which are stimulated to grow by testosterone. Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink.
|
| | BUSERELIN Preparation Products And Raw materials |
|